<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>ID Practice Update</title>
    <link>https://docarcshot.github.io/id-practice-update/</link>
    <description>Selected adult infectious diseases literature with concise clinical summaries and practical takeaways.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 19 Nov 2026 14:52:25 GMT</lastBuildDate>
    <atom:link href="https://docarcshot.github.io/id-practice-update/rss.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Primary Pulmonary Coccidioidomycosis in Persons with Community Acquired Pneumonia in Endemic Areas</title>
      <link>https://docarcshot.github.io/id-practice-update/#coccidioidomycosis-community-acquired-pneumonia-endemic-areas-2026</link>
      <guid isPermaLink="false">id-practice-update:coccidioidomycosis-community-acquired-pneumonia-endemic-areas-2026</guid>
      <pubDate>Thu, 19 Nov 2026 14:52:04 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-11-19. Added 2026-11-19.

Among 496 participants aged at least 14 years who presented with community-acquired pneumonia at Arizona and California sites, 23.4% had primary pulmonary coccidioidomycosis (95% CI 19.9%-27.3%). The adjusted odds of coccidioidomycosis decreased with each year of age (odds ratio 0.98, 95% CI 0.97-1.00), were lower in females than males (odds ratio 0.55, 95% CI 0.33-0.93), and were higher among Hispanic than non-Hispanic participants (odds ratio 1.98, 95% CI 1.08-3.64).

Practical takeaway: For pneumonia after residence in or travel to a Coccidioides-endemic area, especially Arizona or California, include primary pulmonary coccidioidomycosis in the initial differential and obtain appropriate serologic testing when the exposure and syndrome fit. Do not use sex or ethnicity as stand-alone testing rules, and do not interpret this study as support for empiric fluconazole in every endemic-area CAP case; treatment still depends on illness severity, host risk, extent of disease, and guideline-based clinical judgment.

Primary source: https://doi.org/10.1093/ofid/ofag749</description>
    </item>
    <item>
      <title>Chasing Shadows? Antibiotic Treatment for Asymptomatic Bacteriuria in the First 30 Days Post Kidney Transplant</title>
      <link>https://docarcshot.github.io/id-practice-update/#early-kidney-transplant-asb-treatment-2026</link>
      <guid isPermaLink="false">id-practice-update:early-kidney-transplant-asb-treatment-2026</guid>
      <pubDate>Tue, 17 Nov 2026 14:30:53 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-11-16. Added 2026-11-17.

Among 1,851 adult kidney-transplant recipients at one U.S. center, 359 developed 620 asymptomatic-bacteriuria episodes during the first 30 days after transplantation. Antibiotics were given to 72 patients for 112 episodes; 287 patients with 508 episodes were not treated. Treatment was not associated with lower one-year biopsy-proven rejection in propensity-adjusted analysis (hazard ratio 1.26, 95% CI 0.44-3.56) or inverse-probability-weighted analysis (hazard ratio 1.03, 95% CI 0.34-3.19).

Practical takeaway: For a kidney-transplant recipient within 30 days of surgery, confirm that bacteriuria is truly asymptomatic before prescribing and review the result with the transplant team rather than treating automatically. Consider symptoms that may be muted, graft tenderness, fever or systemic findings, upcoming urologic manipulation, urinary obstruction, catheters or stents, and the organism. This observational study supports stewardship review; it is not a randomized basis for universally withholding antibiotics or abandoning local transplant protocols.

Primary source: https://doi.org/10.1093/ofid/ofag750</description>
    </item>
    <item>
      <title>Oral versus intravenous postoperative antibiotics after laparoscopic appendectomy following complicated appendicitis: an open-label cluster-randomized cluster-crossover multiperiod non-inferiority study</title>
      <link>https://docarcshot.github.io/id-practice-update/#oral-iv-antibiotics-complicated-appendicitis-2026</link>
      <guid isPermaLink="false">id-practice-update:oral-iv-antibiotics-complicated-appendicitis-2026</guid>
      <pubDate>Sun, 15 Nov 2026 14:49:49 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-11-13. Added 2026-11-15.

This pragmatic trial allocated 1,021 adults at 12 Danish hospitals to three days of oral or intravenous antibiotics after laparoscopic appendectomy for complicated appendicitis. Intra-abdominal abscess occurred in 39/567 oral-therapy patients and 22/454 IV-therapy patients; weighted 30-day incidences were 6.8% versus 4.9% (risk difference 1.9 percentage points, 90% CI -0.4 to 4.2), meeting the prespecified 5-point noninferiority margin. The per-protocol analysis also met noninferiority (4.9% versus 3.0%; risk difference 1.8 points, 90% CI -0.3 to 3.9).

Practical takeaway: Consider oral postoperative therapy instead of continued IV therapy when laparoscopic source control is adequate, the patient is clinically stable, an active and absorbable oral regimen is available, and follow-up and return precautions are reliable. Incorporate the higher readmission signal into discharge planning; the study does not support oral therapy for uncontrolled infection, hemodynamic instability, impaired absorption, or patients outside the studied postoperative setting.

Primary source: https://doi.org/10.1093/bjs/znag141</description>
    </item>
    <item>
      <title>Estimation of mRNA-1283 vs BNT162b2 COVID-19 Vaccine Effectiveness in Older US Veterans</title>
      <link>https://docarcshot.github.io/id-practice-update/#mrna1283-bnt162b2-veterans-2026</link>
      <guid isPermaLink="false">id-practice-update:mrna1283-bnt162b2-veterans-2026</guid>
      <pubDate>Fri, 13 Nov 2026 14:57:38 GMT</pubDate>
      <category>Worth knowing</category>
      <description>Published 2026-11-11. Added 2026-11-13.

This target-trial emulation compared LP.8.1-formulated mRNA-1283 with BNT162b2 in 294,499 matched U.S. veterans aged at least 65 years during the 2025-2026 respiratory-virus season. Over 150 days, medically attended COVID-19 occurred in 86/55,349 (0.16%) mRNA-1283 recipients versus 672/239,150 (0.28%) BNT162b2 recipients (adjusted relative vaccine effectiveness 35.9%, 95% credible interval 20.4-49.7%; adjusted risk difference -10.0, 95% credible interval -14.3 to -5.6 events per 10,000 vaccinated people).

Practical takeaway: For an older, high-risk adult choosing between available current-season mRNA COVID-19 vaccines, these data support considering mRNA-1283 when product choice is otherwise unconstrained. Do not delay or forgo vaccination to obtain a specific brand, and do not interpret this observational study as proving causal superiority across future formulations, variants, or populations.

Primary source: https://doi.org/10.1001/jamanetworkopen.2026.44727</description>
    </item>
    <item>
      <title>Does the Timing of Surgical Debridement Affect Outcomes in Septic Arthritis of the Native Hip and Knee? A Propensity-weighted Analysis</title>
      <link>https://docarcshot.github.io/id-practice-update/#native-septic-knee-debridement-timing-2026</link>
      <guid isPermaLink="false">id-practice-update:native-septic-knee-debridement-timing-2026</guid>
      <pubDate>Wed, 11 Nov 2026 14:59:54 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-11-10. Added 2026-11-11.

This Florida all-payer cohort analyzed 3,545 adult admissions for surgically treated native hip or knee septic arthritis. For septic knee arthritis, initial debridement on hospital day 2 or later versus days 0 to 1 was associated with more repeat debridement (133/1,034 [13%] versus 72/1,510 [5%]; adjusted risk ratio 2.40, 95% CI 1.81-3.19; P&lt;.001) and higher 1-year mortality (118/1,034 [11%] versus 88/1,510 [6%]; adjusted risk ratio 1.54, 95% CI 1.17-2.02; P=.002).

Practical takeaway: Once native-knee septic arthritis is established and operative source control is indicated, prioritize debridement on the day of admission or the next hospital day and use a coordinated pathway to avoid preventable delay. The study does not define an hour-level deadline, prove causality, or support a timing recommendation for septic hip arthritis.

Primary source: https://doi.org/10.1097/CORR.0000000000004199</description>
    </item>
    <item>
      <title>Hepatitis B Reactivation and Infection in People with HIV on Tenofovir-Sparing Antiretroviral Therapy</title>
      <link>https://docarcshot.github.io/id-practice-update/#hbv-tenofovir-sparing-art-cfarnet-2026</link>
      <guid isPermaLink="false">id-practice-update:hbv-tenofovir-sparing-art-cfarnet-2026</guid>
      <pubDate>Mon, 09 Nov 2026 15:50:34 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-11-07. Added 2026-11-09.

The U.S. CFAR Network cohort included 5,776 people with HIV without active HBV infection who received at least one tenofovir-sparing ART regimen after May 2014. Over a median 5.3 years of follow-up, 17 HBV infections or reactivations were identified; incident infection occurred at 3.9 per 10,000 person-years and reactivation at 6.0 per 10,000 person-years. ALT of at least 100 U/L within three months occurred in only one incident-infection case.

Practical takeaway: Before starting tenofovir-sparing ART, document HBsAg, anti-HBc, and anti-HBs; vaccinate or revaccinate when indicated and retain a monitoring plan for incident HBV or reactivation. The low observed rate supports use of tenofovir-sparing regimens in appropriately selected patients, but prior HBsAb positivity should not be treated as a guarantee of zero risk.

Primary source: https://doi.org/10.1093/ofid/ofag731</description>
    </item>
    <item>
      <title>Imipenem-cilastatin-funobactam versus imipenem-cilastatin-relebactam in patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia: a phase 3, double-blind, non-inferiority randomised trial</title>
      <link>https://docarcshot.github.io/id-practice-update/#funobactam-habp-vabp-phase3-2026</link>
      <guid isPermaLink="false">id-practice-update:funobactam-habp-vabp-phase3-2026</guid>
      <pubDate>Sat, 07 Nov 2026 14:18:50 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-11-04. Added 2026-11-07.

This multinational phase 3 trial randomized 450 adults with clinically documented or suspected Gram-negative HABP/VABP at 62 hospitals; 449 were included in the modified intention-to-treat analysis. Fourteen-day mortality was 9/299 (3.0%) with imipenem-cilastatin-funobactam and 4/150 (2.7%) with imipenem-cilastatin-relebactam (difference 0.2 percentage points, 95% CI -3.5 to 4.0), meeting the prespecified 10-point noninferiority margin.

Practical takeaway: Track regulatory status and susceptibility data rather than using this investigational regimen now. The trial supports a potential future HABP/VABP option but does not establish superiority or efficacy for specific CRAB, CRE, or DTR Pseudomonas subgroups.

Primary source: https://doi.org/10.1016/S1473-3099(26)00520-7</description>
    </item>
    <item>
      <title>Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial</title>
      <link>https://docarcshot.github.io/id-practice-update/#opti-dor-initial-hiv-weight-2026</link>
      <guid isPermaLink="false">id-practice-update:opti-dor-initial-hiv-weight-2026</guid>
      <pubDate>Sat, 07 Nov 2026 14:18:50 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-07-31. Added 2026-11-07.

Opti-DOR randomized 600 ART-naive adults at two South African sites to doravirine-lamivudine-tenofovir disoproxil fumarate or dolutegravir-emtricitabine-tenofovir alafenamide. At week 48, HIV RNA was below 50 copies/mL in 266/299 (89.0%) versus 273/301 (90.7%); the difference was -1.7 percentage points (95% CI -6.6 to 3.1), meeting the -10-point noninferiority margin. Median weight gain was 3.0 versus 5.0 kg (difference -2.0 kg, 95% CI -3.0 to -1.0; P&lt;.001).

Practical takeaway: Doravirine-lamivudine-tenofovir disoproxil fumarate is a reasonable alternative initial regimen when limiting weight gain is a priority and baseline resistance, renal and bone health, HBV status, and follow-up support are suitable. It is not simply superior to dolutegravir-emtricitabine-tenofovir alafenamide; the regimen components changed together, and rapid viral-load and resistance assessment is important if viremia develops.

Primary source: https://doi.org/10.1001/jama.2026.14762</description>
    </item>
    <item>
      <title>Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?</title>
      <link>https://docarcshot.github.io/id-practice-update/#ertapenem-resistant-higher-order-carbapenems-2026</link>
      <guid isPermaLink="false">id-practice-update:ertapenem-resistant-higher-order-carbapenems-2026</guid>
      <pubDate>Tue, 03 Nov 2026 14:04:28 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-11-03. Added 2026-11-03.

This multicenter prospective cohort included 374 hospitalized patients with invasive ceftriaxone-resistant Enterobacterales infections who received more than 72 hours of definitive imipenem or meropenem. All isolates were susceptible to the administered higher-order carbapenem by broth microdilution and lacked carbapenemase genes; 136/374 (36%) were ertapenem resistant and 238/374 (64%) were ertapenem susceptible. Ertapenem resistance was associated with higher 30-day mortality after inverse-probability weighting (odds ratio 2.24, 95% CI 1.26-3.98; P=.006).

Practical takeaway: For a serious invasive Enterobacterales infection that is ertapenem resistant but imipenem or meropenem susceptible, do not treat the higher-order carbapenem result as automatically reassuring. Confirm the MIC and carbapenemase result, review the resistance mechanism when available, optimize dosing, and consider an active newer agent with ID and stewardship input when illness severity and the full susceptibility profile justify it. This observational study does not establish which alternative is superior.

Primary source: https://doi.org/10.1093/cid/ciag696</description>
    </item>
    <item>
      <title>Long-Acting HIV Therapy in African Adults with Adherence Challenges</title>
      <link>https://docarcshot.github.io/id-practice-update/#impala-long-acting-hiv-adherence-challenges-2026</link>
      <guid isPermaLink="false">id-practice-update:impala-long-acting-hiv-adherence-challenges-2026</guid>
      <pubDate>Tue, 03 Nov 2026 14:04:28 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-14. Added 2026-11-03.

IMPALA randomized 540 adults in Kenya, South Africa, and Uganda who had HIV-1 RNA below 200 copies/mL but suboptimal oral-treatment adherence or care engagement; 537 were included in the primary analysis. At week 48, HIV-1 RNA was below 50 copies/mL in 244/268 (91.0%) assigned injectable cabotegravir-rilpivirine every 8 weeks and 240/269 (89.2%) continuing oral dolutegravir-based therapy (risk difference 1.9 percentage points, 95% CI -3.1 to 6.9), meeting the 10-point noninferiority margin.

Practical takeaway: Adherence challenges alone should not exclude a virologically suppressed patient from long-acting cabotegravir-rilpivirine when reliable injection follow-up can be built. Review prior resistance and HBV status, confirm suppression, and establish a missed-injection and viral-load monitoring plan. The five virologic failures reinforce the need for prompt resistance testing and regimen reassessment if viremia develops.

Primary source: https://doi.org/10.1056/NEJMoa2518753</description>
    </item>
    <item>
      <title>A Randomized Controlled Trial of Cefiderocol Versus Standard Therapy for Gram-negative Bacterial Bloodstream Infections: Benefit and Risk Assessment Using Desirability of Outcome Ranking and Generalized Pairwise Comparisons</title>
      <link>https://docarcshot.github.io/id-practice-update/#cefiderocol-game-changer-door-2026</link>
      <guid isPermaLink="false">id-practice-update:cefiderocol-game-changer-door-2026</guid>
      <pubDate>Fri, 30 Oct 2026 15:35:26 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-09-07. Added 2026-10-30.

In the GAME CHANGER trial&apos;s prespecified outcome-ranking analysis, cefiderocol had a 50.4% probability of a more desirable outcome than standard therapy (95% CI 45.6-55.1%) using DOOR, with a generalized pairwise comparison win ratio of 1.04 (95% CI 0.85-1.28). In the carbapenem-resistant subset, DOOR probability was 46.8% (95% CI 37.4-56.1%).

Practical takeaway: Do not routinely prefer cefiderocol over an active standard regimen solely for broader spectrum. Select therapy based on organism, resistance mechanism, susceptibility, infection source, and patient factors.

Primary source: https://doi.org/10.1093/cid/ciag538</description>
    </item>
    <item>
      <title>Switch to Once-Weekly, Single-Tablet Islatravir-Lenacapavir From Daily Standard of Care for HIV-1 (ISLEND-2)</title>
      <link>https://docarcshot.github.io/id-practice-update/#islend2-weekly-islatravir-lenacapavir-2026</link>
      <guid isPermaLink="false">id-practice-update:islend2-weekly-islatravir-lenacapavir-2026</guid>
      <pubDate>Fri, 30 Oct 2026 15:35:26 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-08-12. Added 2026-10-30.

ISLEND-2 randomized 634 virologically suppressed adults; 626 received once-weekly oral islatravir-lenacapavir (n=314) or continued daily ART (n=312). At week 48, HIV RNA at least 50 copies/mL occurred in 1/314 (0.3%) versus 4/312 (1.3%), a difference of -1.0 percentage points (95.002% CI -3.0 to 1.1), meeting the 4-point noninferiority margin. Treatment-related adverse events occurred in 18% versus less than 1%.

Practical takeaway: Track weekly islatravir-lenacapavir as a potential future switch strategy; verify regulatory status before use and recognize it does not provide HBV-active therapy.

Primary source: https://doi.org/10.1016/S0140-6736(26)01442-X</description>
    </item>
    <item>
      <title>A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis</title>
      <link>https://docarcshot.github.io/id-practice-update/#beat-tb-six-month-rifampicin-resistant-2026</link>
      <guid isPermaLink="false">id-practice-update:beat-tb-six-month-rifampicin-resistant-2026</guid>
      <pubDate>Fri, 30 Oct 2026 15:35:04 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-06-24. Added 2026-10-30.

The South African BEAT Tuberculosis trial randomized 403 participants with pulmonary rifampicin-resistant tuberculosis to a six-month strategy including bedaquiline, linezolid, delamanid, and levofloxacin and/or clofazimine, or a nine-month local standard regimen. Treatment success occurred in 174/202 (86.1%) versus 172/200 (86.0%); adjusted difference -0.2 percentage points (95% CI -6.9 to 6.5), meeting the prespecified 10-point noninferiority margin. Grade 3 or higher adverse events occurred in 31.2% versus 37.0%.

Practical takeaway: Use this evidence in specialist-directed treatment selection, accounting for drug susceptibility, toxicity, interactions, availability, and public-health guidance.

Primary source: https://doi.org/10.1056/NEJMoa2503687</description>
    </item>
    <item>
      <title>Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia</title>
      <link>https://docarcshot.github.io/id-practice-update/#snap-cefazolin-mssa-bacteremia-2026</link>
      <guid isPermaLink="false">id-practice-update:snap-cefazolin-mssa-bacteremia-2026</guid>
      <pubDate>Fri, 30 Oct 2026 15:34:47 GMT</pubDate>
      <category>Practice changing</category>
      <description>Published 2026-06-17. Added 2026-10-30.

SNAP randomized adults with MSSA bacteremia to cefazolin or flucloxacillin/cloxacillin. Ninety-day mortality was 97/645 (15.0%) with cefazolin versus 109/642 (17.0%) with antistaphylococcal penicillins (adjusted odds ratio 0.81, 95% credible interval 0.59-1.12; posterior probability of noninferiority 99.2%). Acute kidney injury occurred in 92/660 (13.9%) versus 127/648 (19.6%).

Practical takeaway: Cefazolin is an evidence-supported definitive option for MSSA bacteremia. Continue appropriate evaluation for endocarditis, metastatic infection and source control.

Primary source: https://doi.org/10.1056/NEJMoa2506905</description>
    </item>
    <item>
      <title>A Randomized Clinical Trial to Compare Moxifloxacin Versus Azithromycin for the Treatment of Mycoplasma genitalium: The FARTHEST Study</title>
      <link>https://docarcshot.github.io/id-practice-update/#farthest-mgen-moxifloxacin-azithromycin-2026</link>
      <guid isPermaLink="false">id-practice-update:farthest-mgen-moxifloxacin-azithromycin-2026</guid>
      <pubDate>Fri, 30 Oct 2026 15:34:47 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-05-17. Added 2026-10-30.

In 358 adults with Mycoplasma genitalium infection randomized without resistance-guided selection, microbiologic cure was 87.0% with moxifloxacin 400 mg daily for 10 days versus 61.2% with azithromycin 500 mg daily for 6 days (absolute difference 25.8 percentage points, 95% CI 16.5-35.2).

Practical takeaway: Prefer resistance-guided management where available. Consider moxifloxacin rather than empiric azithromycin when susceptibility is unknown, balancing resistance and fluoroquinolone toxicity.

Primary source: https://doi.org/10.1093/cid/ciag317</description>
    </item>
    <item>
      <title>Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin: A Randomized Controlled Trial</title>
      <link>https://docarcshot.github.io/id-practice-update/#stop-vanc-mrsa-nares-icu-cap-rct-2026</link>
      <guid isPermaLink="false">id-practice-update:stop-vanc-mrsa-nares-icu-cap-rct-2026</guid>
      <pubDate>Fri, 30 Oct 2026 15:21:06 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-06-02. Added 2026-10-30.

STOP-Vanc randomized 277 adults in an ICU with suspected community-acquired pneumonia to usual care with or without added MRSA nasal PCR testing and a targeted discontinuation alert for negative results. The negative predictive value of nasal PCR in the intervention arm was 98.9%. Estimated vancomycin-free hours alive over 7 days were 109.7 with testing versus 105.7 with usual care (adjusted difference 4 hours, 95% CI -9.5 to 18.2; P=.458).

Practical takeaway: A negative MRSA nasal PCR remains useful evidence against MRSA pneumonia, but ordering the test alone does not ensure earlier vancomycin discontinuation. Pair testing with active stewardship, clear stopping criteria, and review of whether empiric MRSA coverage was indicated initially.

Primary source: https://doi.org/10.1093/cid/ciag295</description>
    </item>
    <item>
      <title>State-of-the-Art Review: Native Joint Septic Arthritis Epidemiology, Pathogenesis, Microbiology, Diagnosis, Management, and Outcomes</title>
      <link>https://docarcshot.github.io/id-practice-update/#native-joint-septic-arthritis-state-of-art-2026</link>
      <guid isPermaLink="false">id-practice-update:native-joint-septic-arthritis-state-of-art-2026</guid>
      <pubDate>Fri, 30 Oct 2026 15:20:06 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-27. Added 2026-10-30.

This state-of-the-art review synthesizes evidence on native joint septic arthritis, including limitations of synovial leukocyte thresholds and cultures, emerging molecular testing, pathogen-specific empiric treatment, surgical source control, antibiotic duration, and transition to oral therapy. Staphylococcus aureus predominates; the review estimates approximately one-quarter of cases are culture negative across included cohorts.

Practical takeaway: Obtain blood cultures and synovial sampling before empiric antibiotics when clinically feasible, assess promptly for surgical drainage, and tailor therapy to cultures and host risk factors. Do not use a single synovial WBC cutoff to exclude infection. Consider oral step-down when source control, clinical response, microbiology, oral absorption, and adherence permit; individualize total duration by joint, organism, and complications.

Primary source: https://academic.oup.com/cid/article/83/4/499/9004010</description>
    </item>
    <item>
      <title>Performance of the recent Duke criteria versions in patients with suspected infective endocarditis and sufficient cardiac imaging: The more things change, the more they remain the same</title>
      <link>https://docarcshot.github.io/id-practice-update/#duke-criteria-endocarditis-performance-2026</link>
      <guid isPermaLink="false">id-practice-update:duke-criteria-endocarditis-performance-2026</guid>
      <pubDate>Fri, 30 Oct 2026 13:27:05 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-29. Added 2026-10-30.

Investigators compared the 2015 Duke-ESC, 2023 Duke-ISCVID, and 2023 Duke-ESC criteria with final Endocarditis Team diagnosis in 3,448 suspected infective endocarditis episodes evaluated with guideline-concordant cardiac imaging at two Swiss university hospitals from 2014 through 2025; 1,302/3,448 (38%) were ultimately diagnosed as infective endocarditis. When only definite classification counted as positive, sensitivity increased from 63% (95% CI 60%-66%) with 2015 Duke-ESC to 74% (95% CI 71%-76%) with 2023 Duke-ISCVID and 71% (95% CI 68%-73%) with 2023 Duke-ESC.

Practical takeaway: Use the 2023 criteria to structure evidence, not as a stand-alone clinical diagnosis or rule-out test. A possible classification still requires integration of organism and serial culture data, echocardiography and additional imaging, extracardiac findings, treatment response, and multidisciplinary review. Likewise, counting definite plus possible disease as a positive test can substantially overcall infective endocarditis, especially with the 2023 Duke-ISCVID criteria.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag688/9004404</description>
    </item>
    <item>
      <title>Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV: October 27, 2026 Update</title>
      <link>https://docarcshot.github.io/id-practice-update/#nih-hiv-guidelines-universal-statin-age-40-75-2026</link>
      <guid isPermaLink="false">id-practice-update:nih-hiv-guidelines-universal-statin-age-40-75-2026</guid>
      <pubDate>Wed, 28 Oct 2026 13:59:51 GMT</pubDate>
      <category>Practice changing</category>
      <description>Published 2026-10-27. Added 2026-10-28.

The NIH Adult and Adolescent Antiretroviral Guidelines now recommend statin therapy for every person with HIV aged 40-75 years, regardless of LDL cholesterol or estimated 10-year ASCVD risk. The recommendation is anchored by REPRIEVE, which randomized 7,769 adults with HIV on ART and low-to-intermediate cardiovascular risk to pitavastatin or placebo. Over a median 5.6 years, major adverse cardiovascular events occurred at 4.95 versus 7.77 per 1,000 person-years (hazard ratio 0.64, 95% CI 0.48-0.84).

Practical takeaway: For a patient with HIV aged 40-75 years without a contraindication, initiate at least a moderate-intensity statin even when LDL cholesterol and calculated ASCVD risk are low. Check the complete ART regimen for statin interactions and dose limits, especially with pharmacokinetic boosters, and discuss the small excess risks of diabetes and muscle symptoms. Defer initiation during pregnancy and stop the statin if pregnancy occurs.

Primary source: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new?view=full</description>
    </item>
    <item>
      <title>FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment</title>
      <link>https://docarcshot.github.io/id-practice-update/#fda-hibsago-bepirovirsen-chronic-hepatitis-b-2026</link>
      <guid isPermaLink="false">id-practice-update:fda-hibsago-bepirovirsen-chronic-hepatitis-b-2026</guid>
      <pubDate>Mon, 26 Oct 2026 13:25:01 GMT</pubDate>
      <category>Practice changing</category>
      <description>Published 2026-10-20. Added 2026-10-26.

The FDA approved Hibsago (bepirovirsen), the first HBV mRNA-directed antisense oligonucleotide, in combination with nucleos(t)ide analogue reverse-transcriptase inhibitor therapy for selected adults with chronic hepatitis B without cirrhosis. In the identically designed B-Well 1 and B-Well 2 phase 3 trials, 1,834 treated participants had baseline HBsAg greater than 100 to 3,000 IU/mL and suppressed HBV DNA. Twenty-four weeks after eligible participants stopped all HBV therapy, sustained HBV DNA suppression with undetectable HBsAg occurred in 127/650 (20%) versus 0/328 in B-Well 1 and 106/570 (19%) versus 0/286 in B-Well 2; stratified rate differences were 17 percentage points (95% CI 14.6-20.3) and 13 points (95% CI 10.4-16.1), respectively (both P&lt;.0001).

Practical takeaway: Consider Hibsago only for adults without cirrhosis who have received stable nucleos(t)ide analogue therapy for at least six months, have suppressed HBV DNA, and have HBsAg no higher than 3,000 IU/mL on an FDA-authorized assay. Before and during therapy, follow HBsAg, HBV DNA, ALT, bilirubin, platelets, eGFR, and urine albumin-creatinine ratio; the label requires at least weekly liver tests through week 12, weekly platelets, and eGFR every other week. Continue background therapy for at least 24 weeks after Hibsago, then stop it only if all label criteria are met and frequent post-treatment monitoring can be assured. Do not stop an HIV-active nucleos(t)ide regimen without HIV-specific review.

Primary source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment</description>
    </item>
    <item>
      <title>Cefepime-Zidebactam for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria, Including Metallo-beta-Lactamase Producers: A Phase 2, Open-Label, Single-Arm, Multicenter Study</title>
      <link>https://docarcshot.github.io/id-practice-update/#cefepime-zidebactam-carbapenem-resistant-mbl-phase2-2026</link>
      <guid isPermaLink="false">id-practice-update:cefepime-zidebactam-carbapenem-resistant-mbl-phase2-2026</guid>
      <pubDate>Sat, 24 Oct 2026 13:58:58 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-23. Added 2026-10-24.

In this prospective phase 2 study, 72 adults with carbapenem-resistant Gram-negative infections received intravenous cefepime-zidebactam for 7-21 days; 68 entered the microbiologic intention-to-treat population and 60 were clinically and microbiologically evaluable. Metallo-beta-lactamases, predominantly NDM, were present in 56/68 qualifying isolates (82.4%), and 35/60 evaluable infections (58.3%) were complicated UTI or acute pyelonephritis. Investigator-assessed clinical cure at test of cure was 55/60 (91.7%, 95% CI 81.6%-97.2%), with a favorable microbiologic outcome in 54/60 (90.0%).

Practical takeaway: For an adult with a susceptible carbapenem-resistant Gram-negative infection, cefepime-zidebactam is now a clinically supported option, with especially relevant activity against MBL/NDM producers. Use the FDA-labeled dose with renal adjustment and organism-specific susceptibility testing. Do not infer comparative superiority or routinely extrapolate the high cure rate to bacteremia, pneumonia, or other non-urinary syndromes, which were represented by small numbers in this uncontrolled study.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag665/8993844</description>
    </item>
    <item>
      <title>Randomized Trial Comparing Minocycline-EDTA-Ethanol Lock to Standard-of-Care Antibiotic Lock for Management of Central Line-Associated Bloodstream Infection</title>
      <link>https://docarcshot.github.io/id-practice-update/#minocycline-edta-ethanol-lock-clabsi-rct-2026</link>
      <guid isPermaLink="false">id-practice-update:minocycline-edta-ethanol-lock-clabsi-rct-2026</guid>
      <pubDate>Tue, 20 Oct 2026 13:26:27 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-16. Added 2026-10-20.

At 34 centers in the United States, Puerto Rico, and India, investigators randomized 241 patients aged at least 12 years with CLABSI and a long-term central venous catheter to systemic antibiotics plus minocycline-EDTA-25% ethanol lock therapy or a site-specific standard-of-care antimicrobial lock; 228 received study lock therapy. Catheter retention was 57% with minocycline-EDTA-ethanol versus 38% with standard lock therapy (P=.0025). Median time to catheter failure was not estimable versus 33 days in the intention-to-treat analysis (hazard ratio 0.53; P=.0006) and not estimable versus 35 days in the modified intention-to-treat analysis (hazard ratio 0.50; P=.0005).

Practical takeaway: This trial supports minocycline-EDTA-ethanol lock plus active systemic antibiotics as a promising catheter-salvage strategy when retaining long-term access is clinically appropriate. It does not justify retaining a catheter when there is hemodynamic instability, persistent bloodstream infection, metastatic infection, tunnel or pocket infection, or another organism- or syndrome-specific indication for removal. Mino-Lok remains an investigational product without FDA approval, so the result is practice informing rather than an immediately implementable standard.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag660/8931553</description>
    </item>
    <item>
      <title>Short or Long Antibiotic Regimens in Orthopedics</title>
      <link>https://docarcshot.github.io/id-practice-update/#solario-short-systemic-antibiotics-orthopedics-2026</link>
      <guid isPermaLink="false">id-practice-update:solario-short-systemic-antibiotics-orthopedics-2026</guid>
      <pubDate>Sun, 18 Oct 2026 13:07:48 GMT</pubDate>
      <category>Practice changing</category>
      <description>Published 2026-09-16. Added 2026-10-18.

SOLARIO randomized 500 adults at 25 European sites after surgery for confirmed orthopedic infection and implantation of a local-antibiotic carrier to no more than 7 days or at least 4 weeks of systemic antibiotics. In the primary analysis of 475 participants, definite treatment failure by 12 months occurred in 26/234 (11.1%) with short therapy and 34/241 (14.1%) with long therapy; the risk difference was -3.0 percentage points (95% CI -9.0 to 3.0), meeting the prespecified 10-point noninferiority margin.

Practical takeaway: Do not translate this result to &apos;7 days for all prosthetic joint infection or osteomyelitis.&apos; Consider no more than 7 systemic-antibiotic days only after adequate operative source control with an implanted local-antibiotic carrier whose drug or drugs cover the recovered organism, using a multidisciplinary protocol. Continue syndrome-appropriate systemic therapy when infected material is retained, source control is incomplete, local delivery is absent or inactive, or another infection requires systemic treatment.

Primary source: https://www.nejm.org/doi/full/10.1056/NEJMoa2506756</description>
    </item>
    <item>
      <title>Antibiotic Stewardship, Resistance, and Mortality in Vancomycin-Resistant Enterococcus: A Quasi-Experimental Study of Linezolid Restrictions</title>
      <link>https://docarcshot.github.io/id-practice-update/#linezolid-restriction-vre-resistance-mortality-2026</link>
      <guid isPermaLink="false">id-practice-update:linezolid-restriction-vre-resistance-mortality-2026</guid>
      <pubDate>Fri, 16 Oct 2026 13:44:30 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-16. Added 2026-10-16.

Investigators analyzed 521,493 admissions at two academic hospitals from 2008 through 2019 after one hospital introduced linezolid prior authorization in 2011 and stricter criteria with post-prescription review in 2014, using the other hospital as a control. The policies were associated with a 27% reduction in linezolid use (absolute change -0.9 percentage points, 95% CI -1.1 to -0.7; P&lt;.001) and a 41% reduction in linezolid resistance among Enterococcus isolates (absolute change -1.0 percentage point, 95% CI -1.6 to -0.4; P=.003).

Practical takeaway: If linezolid requires authorization, build an urgent exception pathway for patients with prior or current VRE detection plus compatible sepsis or bacteremia. Audit both resistance and patient-centered safety outcomes after restriction, including time to active therapy and mortality in the VRE-positive subgroup. A reduction in drug use or resistance alone is not sufficient evidence that a restriction policy is safe.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag656/8923644</description>
    </item>
    <item>
      <title>Progressing From Association to Causation: Examining Prior Antibiotic Exposure and Antimicrobial Resistance Across Three US Health Systems Using Causal Machine Learning</title>
      <link>https://docarcshot.github.io/id-practice-update/#prior-antibiotic-exposure-resistance-causal-ml-2026</link>
      <guid isPermaLink="false">id-practice-update:prior-antibiotic-exposure-resistance-causal-ml-2026</guid>
      <pubDate>Fri, 16 Oct 2026 13:44:30 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-15. Added 2026-10-16.

Across 1,165,151 culture episodes at three US health systems, investigators used double machine learning with more than 35 measured confounders per site to estimate the effect of antibiotic exposure during the preceding 90 days. Prior fluoroquinolone exposure was associated with an 11.9- and 12.6-percentage-point increase in fluoroquinolone nonsusceptibility at the two primary sites and an 8.6-point increase at the validation site (all P&lt;.001). Positive associations appeared for all seven studied antibiotic classes across all three systems except for an indeterminate sulfonamide estimate at one site.

Practical takeaway: Before selecting empiric therapy for a serious infection, review antibiotic classes received in the prior 90 days together with previous isolates and susceptibilities. Recent same-class exposure should prompt closer scrutiny and often favor an active alternative when illness is severe or source data support resistance risk. It is not an automatic prohibition: local epidemiology, allergy, organ function, infection source, and individual culture history still determine the regimen.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag549/8917373</description>
    </item>
    <item>
      <title>Risk Factors and Therapeutic Consequences of Virologic Failure With Long-Acting Cabotegravir Plus Rilpivirine in the Dat’AIDS Cohort</title>
      <link>https://docarcshot.github.io/id-practice-update/#cabotegravir-rilpivirine-long-acting-failure-dataids-2026</link>
      <guid isPermaLink="false">id-practice-update:cabotegravir-rilpivirine-long-acting-failure-dataids-2026</guid>
      <pubDate>Fri, 16 Oct 2026 13:44:30 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-14. Added 2026-10-16.

The French Dat’AIDS cohort followed 2,196 adults with virologic suppression who switched to long-acting cabotegravir plus rilpivirine from December 2021 through December 2023. Over a median 13 months, virologic failure occurred in 42/2,196 (1.9%) after a median 103 days. Among 26 failures with successful genotyping, treatment-emergent resistance was detected in 13/26 (50%); susceptibility was retained more often to doravirine (92% by ANRS and 96% by Stanford interpretation) than to dolutegravir or bictegravir (58% and 65%, respectively).

Practical takeaway: Long-acting cabotegravir plus rilpivirine remained effective for most selected patients, but review the full resistance history, duration of suppression, nadir CD4 count, and BMI before switching. When low-level viremia or rebound occurs, obtain prompt integrase and reverse-transcriptase resistance testing while viremia is detectable and reassess injection timing, drug interactions, and adherence. Do not assume spontaneous resuppression excludes clinically important resistance that may compromise dolutegravir or bictegravir.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag654/8916478</description>
    </item>
    <item>
      <title>Cephalexin 500 mg Four Times Daily vs. 1000 mg Three Times Daily for the Treatment of Uncomplicated Cellulitis</title>
      <link>https://docarcshot.github.io/id-practice-update/#cephalexin-tid-vs-qid-cellulitis-2026</link>
      <guid isPermaLink="false">id-practice-update:cephalexin-tid-vs-qid-cellulitis-2026</guid>
      <pubDate>Fri, 16 Oct 2026 13:44:30 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-14. Added 2026-10-16.

This multicenter retrospective cohort compared 150 adults prescribed cephalexin 500 mg four times daily with 150 prescribed 1,000 mg three times daily for 5-10 days of uncomplicated lower-extremity cellulitis. Treatment failure occurred in 6.7% with 500 mg four times daily and 5.3% with 1,000 mg three times daily (P=.627). Median time to failure was seven days (IQR 3-8) versus five days (IQR 2.5-8; P=.633), and unplanned revisit or hospitalization occurred in 4.0% versus 2.7% (P=.52).

Practical takeaway: For uncomplicated nonpurulent lower-extremity cellulitis treated with cephalexin, 1,000 mg three times daily is a reasonable alternative to 500 mg four times daily when fewer daily doses may improve feasibility. Adjust for renal function and retain syndrome-specific decisions about MRSA coverage and source control. Reassess promptly if systemic illness, rapid progression, abscess, treatment failure, or a deeper infection is suspected.

Primary source: https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofag681/8916480</description>
    </item>
    <item>
      <title>Outpatient Antibiotic Fills and 30-Day Readmission Following Patient-Directed Discharge in Drug Use-Associated Infective Endocarditis in a National Medicaid Cohort</title>
      <link>https://docarcshot.github.io/id-practice-update/#patient-directed-discharge-endocarditis-antibiotic-fills-2026</link>
      <guid isPermaLink="false">id-practice-update:patient-directed-discharge-endocarditis-antibiotic-fills-2026</guid>
      <pubDate>Fri, 16 Oct 2026 13:44:30 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-14. Added 2026-10-16.

Using national Medicaid data from 2016 through 2022, investigators identified 19,808 adults aged 18-64 years with a new drug use-associated infective endocarditis episode; 5,519/19,808 (27.9%) had a patient-directed discharge. An outpatient antibiotic was filled within three days by 17.1% after patient-directed discharge versus 44.2% after other discharges (adjusted odds ratio [aOR] 0.25, 95% CI 0.20-0.33). Patient-directed discharge was associated with higher 30-day readmission (aOR 1.91, 95% CI 1.65-2.21).

Practical takeaway: Anticipate patient-directed discharge early and prepare a harm-reduction plan that can be executed the same day: dispense medication at bedside when possible, select the best feasible oral or long-acting regimen, arrange rapid follow-up, and integrate addiction treatment and naloxone. The study does not establish that any particular outpatient regimen is equivalent to standard endocarditis therapy, but it strongly supports offering active treatment rather than withholding antibiotics because the ideal plan cannot be completed.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag649/8916476</description>
    </item>
    <item>
      <title>Recurrent and Relapsing Catheter-Related Bloodstream Infections in Patients Requiring Long-term Vascular Access</title>
      <link>https://docarcshot.github.io/id-practice-update/#recurrent-relapsing-crbsi-long-term-access-2026</link>
      <guid isPermaLink="false">id-practice-update:recurrent-relapsing-crbsi-long-term-access-2026</guid>
      <pubDate>Mon, 12 Oct 2026 13:58:15 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-10. Added 2026-10-12.

This state-of-the-art review synthesizes evidence and expert guidance through June 2026 for adults and children with recurrent or relapsing infection involving long-term vascular access. It emphasizes paired peripheral and catheter blood cultures: catheter cultures turning positive at least two hours earlier support catheter-related bloodstream infection, with reported sensitivity and specificity of 98% and 89% in prolonged catheterization, although sensitivity for Staphylococcus aureus was only 42% despite 100% specificity in one port-heavy study. The review recommends catheter removal for S. aureus, Candida species, mycobacteria, persistent bloodstream infection, hemodynamic instability, metastatic infection, suppurative thrombophlebitis, tunnel infection, port-pocket abscess, or relapse after directed therapy.

Practical takeaway: For recurrent or relapsing CRBSI, first confirm the source with properly timed paired cultures and look for an uncorrected pocket, tunnel, thrombus, endovascular, or metastatic focus. Remove the catheter when the organism or clinical course makes eradication unlikely. Reserve salvage with systemic plus lock therapy for stable patients with less virulent organisms and a compelling access-preservation need, using early and post-treatment cultures to detect failure. Involve vascular access or interventional radiology early rather than losing future venous pathways through serial unplanned replacements.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag559/8899426</description>
    </item>
    <item>
      <title>Tongue Swab Mycobacterium tuberculosis Quantitative Polymerase Chain Reaction for Community Screening of Asymptomatic Tuberculosis Versus Clinic-Based Triage of Symptomatic Tuberculosis</title>
      <link>https://docarcshot.github.io/id-practice-update/#tongue-swab-tb-community-screening-2026</link>
      <guid isPermaLink="false">id-practice-update:tongue-swab-tb-community-screening-2026</guid>
      <pubDate>Sat, 10 Oct 2026 13:13:44 GMT</pubDate>
      <category>Practice informing</category>
      <description>Published 2026-10-09. Added 2026-10-10.

At six South African sites, investigators compared tongue-swab Mycobacterium tuberculosis qPCR in 180 adult household contacts, including 44 with microbiologically confirmed TB, with testing in 654 symptomatic clinic attendees, including 217 with TB. High-volume qPCR sensitivity was 15/44 (34.1%, 95% CI 20.5%-49.9%) in household contacts versus 67/105 (63.8%, 95% CI 53.9%-73.0%) in a propensity-matched clinic subset (P=.0007); specificity was 125/136 (91.9%) and 201/213 (94.4%), respectively. Among asymptomatic household contacts with TB, sensitivity was 13/37 (35.1%).

Practical takeaway: Do not use a negative tongue-swab qPCR result to exclude TB in asymptomatic household contacts or as a stand-alone community-screening test. The result does not overturn the WHO-endorsed role of tongue swabs with near-point-of-care platforms for selected people unable to produce sputum, but that indication was not tested here. For community case finding, retain radiographic and sputum-based pathways when feasible and require population-specific validation before extrapolating performance from symptomatic clinic cohorts.

Primary source: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag443/8889072</description>
    </item>
  </channel>
</rss>
